GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EV Biologics Inc (OTCPK:YECO) » Definitions » Price-to-Free-Cash-Flow

EV Biologics (EV Biologics) Price-to-Free-Cash-Flow : N/A (As of May. 21, 2024)


View and export this data going back to 2015. Start your Free Trial

What is EV Biologics Price-to-Free-Cash-Flow?

As of today (2024-05-21), EV Biologics's share price is $0.5741. EV Biologics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2017 was $-11.49. Hence, EV Biologics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for EV Biologics's Price-to-Free-Cash-Flow or its related term are showing as below:

YECO's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 32.97
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

EV Biologics's Free Cash Flow per Share for the three months ended in Dec. 2017 was $0.00. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-11.49.


EV Biologics Price-to-Free-Cash-Flow Historical Data

The historical data trend for EV Biologics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EV Biologics Price-to-Free-Cash-Flow Chart

EV Biologics Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17
Price-to-Free-Cash-Flow
- - 15.61 - -

EV Biologics Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17 Dec17
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of EV Biologics's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, EV Biologics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EV Biologics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EV Biologics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where EV Biologics's Price-to-Free-Cash-Flow falls into.



EV Biologics Price-to-Free-Cash-Flow Calculation

EV Biologics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.5741/-11.489
=N/A

EV Biologics's Share Price of today is $0.5741.
EV Biologics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.49.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

EV Biologics  (OTCPK:YECO) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


EV Biologics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of EV Biologics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


EV Biologics (EV Biologics) Business Description

Traded in Other Exchanges
N/A
Address
1621 Central Avenue, Cheyenne, WY, USA, 82001
EV Biologics Inc is developing the extraordinary biological properties of extracellular vesicles (EVs) to create the next generation of diagnostic modalities and safe, effective biotherapeutics to improve outcomes of serious clinical conditions, increase natural longevity and transform lives.
Executives
Daniel S Mckinney director, 10 percent owner, officer: CEO TWO IFC, 19TH FLOOR, 8 FINANCE STREET, CENTRAL, HONG KONG F4 000000
Michael W Harlan director C/O WASTE CONNECTIONS, INC., 610 APPLEWOOD CRESCENT, SUITE 200, VAUGHAN A6 L4K 0C3

EV Biologics (EV Biologics) Headlines

From GuruFocus

EV Biologics Updates on NFT Dividend

By ACCESSWIRE ACCESSWIRE 11-12-2021

EV Biologics NFT Dividend Warrant Date

By ACCESSWIRE ACCESSWIRE 07-30-2021

EV Biologics Signs Listing Agreement With INX

By ACCESSWIRE ACCESSWIRE 11-11-2021

EV Biologics Signs LOI with Lonza Cell & Gene Therapy

By ACCESSWIRE ACCESSWIRE 07-22-2021

EV Biologics Signs MSA with LONZA Cell & Gene Therapy

By ACCESSWIRE ACCESSWIRE 05-17-2022

EV Biologics Launches Excyte with $100 million Valuation

By ACCESSWIRE ACCESSWIRE 08-15-2022

EV Biologics Updates on FINRA

By ACCESSWIRE ACCESSWIRE 01-18-2022